Necitumumab

DRUG18 trials

Sponsors

Eli Lilly and Company, National Cancer Institute (NCI), Vanderbilt-Ingram Cancer Center, ImmunityBio, Inc., AstraZeneca

Conditions

Carcinoma, Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungLocally Advanced Squamous Non-Small Cell Lung CancerMalignant Solid TumorMetastatic Lung Non-Small Cell CarcinomaMetastatic Squamous Non-Small Cell Lung CancerNeoplasm MetastasisNon Small Cell Lung Cancer

Phase 1

A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT01763788

Eli Lilly and CompanySquamous Non-small Cell Lung Cancer

Start: 2013-05-07End: 2018-10-17Updated: 2019-10-25

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT02411591

Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Start: 2015-06-04End: 2019-05-28Updated: 2020-07-09

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

CompletedNCT02451930

Eli Lilly and CompanyStage IV Non-Small Cell Lung Cancer

Start: 2015-09-04End: 2019-09-17Updated: 2020-10-05

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Active, not recruitingNCT02496663

National Cancer Institute (NCI)Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Start: 2016-05-11End: 2027-06-30Target: 138Updated: 2026-04-03

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

CompletedNCT02789345

Eli Lilly and CompanyNon-small Cell Lung Cancer

Start: 2016-10-24End: 2022-05-09Updated: 2024-02-05

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

TerminatedNCT03054038

Vanderbilt-Ingram Cancer CenterNon-Small Cell Lung Carcinoma

Start: 2017-07-20End: 2022-03-23Updated: 2022-04-14

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

TerminatedNCT03387111

ImmunityBio, Inc.Squamous Cell Carcinoma

Start: 2018-01-09End: 2021-01-11Updated: 2024-08-05

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Active, not recruitingNCT04285671

Jonsson Comprehensive Cancer CenterMetastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8 +2

Start: 2021-01-29End: 2027-12-02Updated: 2026-03-10

Phase 2

A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin

CompletedNCT01606748

Eli Lilly and CompanyMalignant Solid Tumor

Start: 2012-08-31End: 2016-06-30Updated: 2019-09-30

A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

CompletedNCT01624467

Eli Lilly and CompanySolid Tumors

Start: 2012-08-31End: 2015-06-30Updated: 2016-07-25

A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

CompletedNCT01769391

Eli Lilly and CompanySquamous Non Small Cell Lung Cancer

Start: 2013-01-31End: 2017-07-31Updated: 2019-09-20

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

CompletedNCT01788566

Eli Lilly and CompanyNon-small Cell Lung Cancer

Start: 2013-03-31End: 2015-12-31Updated: 2016-06-27

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

CompletedNCT02392507

Eli Lilly and CompanyCarcinoma, Non-Small Cell Lung Cancer (NSCLC)

Start: 2015-10-12End: 2019-11-06Updated: 2020-11-19

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

TerminatedNCT02443337

Eli Lilly and CompanyNon-small Cell Lung Cancer Metastatic

Start: 2015-07-31End: 2017-09-30Updated: 2020-12-09

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

WithdrawnNCT02941601

Eli Lilly and CompanyLocally Advanced Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer

Start: 2016-11-30End: 2019-02-28Updated: 2019-09-27

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Active, not recruitingNCT03944772

AstraZenecaNon-Small Cell Lung Cancer

Start: 2019-06-25End: 2025-05-06Updated: 2025-01-30

Phase 3

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

CompletedNCT00981058

Eli Lilly and CompanyNon Small Cell Lung Cancer

Start: 2010-01-07End: 2024-05-30Updated: 2025-06-18

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

CompletedNCT00982111

Eli Lilly and CompanyNon Small Cell Lung Cancer

Start: 2009-11-02End: 2020-12-23Updated: 2022-01-11

Related Papers

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

2026-03-06

Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.

2025-10-21

Target Aggregate Data Adjustment Method for Transportability Analysis Utilizing Summary‐Level Data From the Target Population

Pharmaceutical Statistics2025-08-061 citations

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

JCO Precision Oncology2025-06-016 citations

UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer.

Journal of Clinical Oncology2023-06-01

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature Communications2023-02-27209 citations

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.

2023-01-036 citations

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <i>MET</i> -Amplified Non–Small Cell Lung Cancer: TATTON

Cancer Discovery2022-10-20142 citations

Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study

Cancer Research2022-06-1510 citations

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology2022-06-0111 citations

Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study

Cancer Research2021-07-014 citations

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

2021-06-2560 citations

Use of deep learning frameworks to detect super-responder and super-survivor stage IV squamous non-small-cell lung cancer (NSCLC) patients treated with a gemcitabine and cisplatin combination.

Journal of Clinical Oncology2021-05-202 citations

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.

2021-05-0312 citations

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i> -mutant Non–small Cell Lung Cancer

Clinical Cancer Research2020-10-1248 citations

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

Journal of Clinical Oncology2019-05-2018 citations

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Lung Cancer2019-01-1638 citations

Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive <i>EGFR</i>-mutant NSCLC.

Journal of Clinical Oncology2018-05-204 citations

Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.

Journal of Clinical Oncology2018-05-202 citations

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Molecular Cancer Therapeutics2018-01-01

9 more papers not shown